Elham Sardar1, Perrine Dusser2, Antoine Rousseau3, Bahram Bodaghi4, Marc Labetoulle3, Isabelle Koné-Paut2. 1. Pediatric Rheumatology, Centre de Référence des Maladies Auto-Inflammatoires, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Sud University Hospital, Le Kremlin-Bicêtre, France. Electronic address: sardar.elham@gmail.com. 2. Pediatric Rheumatology, Centre de Référence des Maladies Auto-Inflammatoires, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Sud University Hospital, Le Kremlin-Bicêtre, France. 3. Department of Ophthalmology, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, DHU Vision and Handicaps, Paris-Sud University, Le Kremlin-Bicêtre, France. 4. Ophtalmology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris VI, Paris, France.
Abstract
OBJECTIVE: To evaluate treatment, ocular complications and outcomes of children with pediatric uveitis not associated with juvenile idiopathic arthritis. STUDY DESIGN: This was a retrospective chart review of pediatric uveitis in children under 16 years of age, recruited from the pediatric rheumatology department at Bicêtre Hospital from 2005 to 2015. Patients with juvenile idiopathic arthritis-associated and infectious uveitis were excluded. We used the Standardization of Uveitis Nomenclature Working Group to classify uveitis, disease activity, and treatment end points. RESULTS: We enrolled 56 patients and 102 affected eyes. The mean age at diagnosis was 10 ± 3.5 years (range 3-15), and the mean follow-up 4.2 ± 3.3 years (1-15). The main diagnoses were idiopathic (55%), Behçet disease (15%), and sarcoidosis (5%). The main localization was panuveitis in 44 of 102 eyes (43%). Corticosteroid sparing treatment was needed in 62 of 102 eyes (60%). Second-line therapies included methotrexate and azathioprine, and the third-line therapy was a biologic agent, mainly infliximab, in 33 of 102 eyes (32%). Infliximab achieved uveitis inactivity in 14 of 18 eyes (80%), in all etiologies. Severe complications were present in 68 of 102 eyes (67%). The most common were synechiae 33% of eyes, cataract (20%), and macular edema (25%). Of these, 37% were present at diagnosis. Remission was achieved in 22 of 102 eyes (21%). CONCLUSIONS: Conventional therapies were insufficient to treat many of the cases of posterior or panuveitis. This study underlines the need for earlier and more aggressive treatment and antitumor necrosis factor-α therapy was rapidly efficient in most cases of refractory uveitis.
OBJECTIVE: To evaluate treatment, ocular complications and outcomes of children with pediatric uveitis not associated with juvenile idiopathic arthritis. STUDY DESIGN: This was a retrospective chart review of pediatric uveitis in children under 16 years of age, recruited from the pediatric rheumatology department at Bicêtre Hospital from 2005 to 2015. Patients with juvenile idiopathic arthritis-associated and infectious uveitis were excluded. We used the Standardization of Uveitis Nomenclature Working Group to classify uveitis, disease activity, and treatment end points. RESULTS: We enrolled 56 patients and 102 affected eyes. The mean age at diagnosis was 10 ± 3.5 years (range 3-15), and the mean follow-up 4.2 ± 3.3 years (1-15). The main diagnoses were idiopathic (55%), Behçet disease (15%), and sarcoidosis (5%). The main localization was panuveitis in 44 of 102 eyes (43%). Corticosteroid sparing treatment was needed in 62 of 102 eyes (60%). Second-line therapies included methotrexate and azathioprine, and the third-line therapy was a biologic agent, mainly infliximab, in 33 of 102 eyes (32%). Infliximab achieved uveitis inactivity in 14 of 18 eyes (80%), in all etiologies. Severe complications were present in 68 of 102 eyes (67%). The most common were synechiae 33% of eyes, cataract (20%), and macular edema (25%). Of these, 37% were present at diagnosis. Remission was achieved in 22 of 102 eyes (21%). CONCLUSIONS: Conventional therapies were insufficient to treat many of the cases of posterior or panuveitis. This study underlines the need for earlier and more aggressive treatment and antitumor necrosis factor-α therapy was rapidly efficient in most cases of refractory uveitis.
Authors: Megan Cann; Athimalaipet V Ramanan; Andrew Crawford; Andrew D Dick; Sarah L N Clarke; Fatima Rashed; Catherine M Guly Journal: Pediatr Rheumatol Online J Date: 2018-08-06 Impact factor: 3.054
Authors: Roos A W Wennink; Viera Kalinina Ayuso; Weiyang Tao; Eveline M Delemarre; Joke H de Boer; Jonas J W Kuiper Journal: Transl Vis Sci Technol Date: 2022-02-01 Impact factor: 3.283